Organizational barriers to using long-acting injectable antipsychotics in practice.

Organizational barriers to using long-acting injectable antipsychotics in practice.

J Clin Psychiatry. 2014 Jun;75(6):e16

Authors: Kane JM

Abstract
Patients with schizophrenia who have been nonadherent to oral antipsychotics may experience better outcomes with long-acting injectable (LAI) antipsychotics. Studies have shown that LAI medications help prevent relapse and rehospitalization in schizophrenia. Despite the evidence that they are beneficial, LAI antipsychotics continue to be underutilized in the United States, partly due to organizational barriers such as concerns about the time and effort related to their use, the costs, and misunderstanding and overall lack of experience on the part of medical staff and patients alike. Doctors and the entire treatment team should become educated on the use and benefits of LAI medications, which they can then impart to their patients and their families, and create treatment plans for the betterment of the patients.

PMID: 25004193 [PubMed - as supplied by publisher]